Eurobio Scientific Team
Executive Committee

Denis Fortier
Chief Executive Officer
Denis Fortier
Denis Fortier is Chairman and CEO of Eurobio Scientific since June 2023. He is particularly in charge of R&D, production, export and business development. He was previously a member of Eurobio Scientific's Management Board since 2017, Director of Eurobio Scientific, and General Manager of the Group since 2019.
Denis Fortier has more than 30 years of experience in in vitro diagnostics and the biotechnology industry, and has dual experience as a leader and entrepreneur. With a Master's degree in Biotechnology and Business, he began his career by holding various marketing and commercial positions in diagnostics companies. He became International Director and then Head of Business Development at diagnostics company BMD (now Theradiag). He then joined the General Management of Inodiag, a start-up in the field of diagnostics for infectious diseases, where he was in charge of development and financing.
In 2010, he acquired with Jean-Michel Carle Grandmougin the Eurobio laboratories which he joined as General Manager to oversee production, R&D, business development and export. He is a member of the Entreprendre network, to help start businesses and follow up young entrepreneurs.
Denis Fortier owns approximately 34% of the EurobioNext holding company which holds approximately 30% of Eurobio Scientific's capital.

Cathie Marsais
Chief Operations Officer
Cathie Marsais
Cathie Marsais joined Eurobio Scientific in 2007 as Quality Manager. Member of the EUROBIO SCIENTIFIC Group Executive Committee, she is currently Deputy General Director in France and is in charge of operations (Supply Chain, production, R&D, Quality and Regulatory Services. She is also the COO of the Eurobio Scientific group and works transversally with the group's operational teams.
She has 18 years of experience in the field of in vitro diagnostics and medical devices. With scientific and regulatory training, she is a referent and representative of EUROBIO SCIENTIFIC management to regulatory bodies and French and European health product agencies.
Cathie Marsais holds a Master's degree in biotechnology and health products from the Pharmaceutical University of Châtenay-Malabry and also holds an Executive MBA from EM Lyon.

Maarten Penning PhD
Chief Technology Officer
Maarten Penning
Maarten Penning joined the EuroBio Scientific Group with the acquisition of GenDx. He has a long experience in all aspects of the development and commercialization of in-vitro diagnostic products and services.
After obtaining his PhD at the Academic Medical Center in Amsterdam, Maarten built his career in science-driven, small scale biotech companies which were active in the field of DNA diagnostics. After a focus on cancer diagnostics within Primagen, he moved to OncoMethylome Sciences (now MDxHealth). There, Maarten was managing the site in Amsterdam where assay development took place, as well as service testing for clinical studies of multiple large pharma companies. Under his supervision, ISO 13485:2003 certification and ISO 17025:2005 accreditation were obtained and production facilities for kit manufacturing were set up. In 2010 Maarten joined GenDx, where he became Chief Technology Officer (CTO) and deputy CEO as of 2016. In these roles, Maarten was instrumental in initiation of new products, which have now evolved in being the most relevant commercial products, as well as in-licensing and purchasing of product lines from third parties.
Per July 1st 2023, Maarten has taken on the roles of General Manager of GenDx and CTO in the Executive Committee of the Eurobio Scientific Group.

Olivier Bosc
Chief Finance Officer
Olivier Bosc
Olivier Bosc is the Deputy Managing Director / CFO of Eurobio Scientific. With their teams, they are responsible for the sound economic management of the group as well as the quality, security and performance of information systems. He oversees mergers, acquisitions and integration activities and the correct allocation of capital and resources.
Olivier joined Eurobio Scientific in 2023. He has more than 25 years of financial and operational management experience. He notably spent 8 years in Audit and Corporate Finance (France, United States) then 14 years at GE Healthcare (France and Russia). For the last 5 years, Olivier worked in hospital management (American Hospital of Paris; Kantys Group)
Olivier graduated from the Ecole Supérieure de Commerce de Toulouse.

Hanneke Merkens PhD
Chief Marketing Officer
Hanneke Merkens
Hanneke Merkens is the Chief Marketing Officer for the EuroBio Scientific group and within this role she is responsible for the global marketing and communication strategies of Eurobio Scientific.
Hanneke holds a PhD in in biochemistry and has worked as a scientific researcher in University Medical Center Utrecht in the Netherlands in the department of medical microbiology. She joined GenDx in 2015 and has had many responsibilities within the organization ranging from managing global the support and education teams, acquiring novel technologies as business development director and she has managed the North American sales team for several years. Hanneke currently oversees the marketing & portfolio teams, is part of the GenDx leadership team. She is the Deputy General Manager at GenDx and since 2023 she participates as CMO in the Eurobio Scientific Executive Committee.

Dejan Drljaca
Chief Commercial Officer
Dejan Drljaca
Dejan lead our company’s commercial expansion as we reinforce our diagnostic portfolio and international expansion.
His strong background in diagnostic industry and global experience matches our long-term vision of growth and will be a key to delivering commercial goals and objectives.
We look forward to the next chapter of strengthening our footprint and enhancing higher quality of care for our customers and patients.
Dejan joins our company from Veracyte Inc where he led IVD portfolio sales globally. His strong diagnostic acumen includes key commercial governance roles at HalioDX, Qiagen, Hologic and Ipsogen where he continuously demonstrated leadership and delivered product revenue growth.

Thomas Moreaux
Chief HR Officer
Thomas Moreaux
Thomas has more than 20 years of experience in Human Resources in various sectors such as IT, banking or service before joining Eurobio Scientific to support the Group in the integration of its subsidiaries as well as in the transformation and the harmonization of its HR practices.
After studying History and Law, Thomas specialized in HR, working first in the fields of training and recruitment, before moving to generalist HR and HR manager positions. He has also managed integration and change management projects in international environments.
Thomas is a member of the French Management Committee and the Group Executive Committee.

Jean-Michel Carle Grandmougin
Business developer Group Director
Jean-Michel Carle Grandmougin
Jean-Michel Carle Grandmougin is a Director of EUROBIO SCIENTIFIC and Deputy General Manager since June 2023. He is in charge of the group's marketing and sales as well as sales in France. He was previously President of EUROBIO SCIENTIFIC's Management Board since 2017, and Chairman and CEO since 2019. He is also President of the EUROBIONEXT holding company which is EUROBIO SCIENTIFIC's reference shareholder.
Jean-Michel Carle Grandmougin has more than 35 years of experience in the field of in vitro diagnostics and research in life sciences. Before becoming a member of the Management Board of the DIAXONHIT Group, he was Chairman and Chief Executive Officer and one of the two partners of the EUROBIO / Capforce Group which was acquired by DIAXONHIT in March 2017. He joined EUROBIO SA in 2006 as Sales Manager and quickly became its Managing Director.
In June 2010, he acquired the company with Denis Fortier and the OTC Asset Management fund which sold back its shares in 2014 to Jean-Michel and Denis. In 1992, he joined BMD (now Theradiag) where he was Sales Director for 13 years before taking responsibility of its German activity. Holder of a bachelor's degree in biology, he began his career in 1985 at Technicon (now Bayer Diagnostics) as a Technical Sales Engineer to become Sales Manager at 30.
Jean-Michel Carle Grandmougin owns approximately 27% of the EUROBIONEXT holding company which holds approximately 30% of EUROBIO SCIENTIFIC's capital.